(Q41132894)

27 September 2017

1 reference

title

Comparison of cefprozil, cefpodoxime proxetil, loracarbef, cefixime, and ceftibuten (English)

1 reference

27 September 2017

1 reference

B S Schatz

1

1 reference

27 September 2017

K T Karavokiros

series ordinal

2

1 reference

27 September 2017

M A Taeubel

series ordinal

3

1 reference

27 September 2017

G S Itokazu

series ordinal

4

1 reference

27 September 2017

language of work or name

English

0 references

publication date

1 March 1996

1 reference

Annals of Pharmacotherapy

27 September 2017

published in

1 reference

27 September 2017

volume

30

1 reference

27 September 2017

issue

3

1 reference

27 September 2017

page(s)

258-268

1 reference

Pharmacokinetics of cefprozil in infants and children

27 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Pharmacokinetic profile of loracarbef

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Ceftibuten. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

The pharmacokinetics of ceftibuten in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Single-dose pharmacokinetics of ceftibuten (SCH 39720) in infants and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Pharmacokinetics of ceftibuten-cis and its trans metabolite in healthy volunteers and in patients with chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Antibacterial activities of cefprozil compared with those of 13 oral cephems and 3 macrolides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from U.S. Medical Centers in 1992 and 1993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY 3522, cefuroxime, cefaclor and cefadroxil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Antibacterial activities of cefpodoxime, cefixime, and ceftriaxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Evaluation of new anti-infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparison of Cefprozil with Other Antibiotic Regimens in the Treatment of Children with Acute Otitis Media

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparative efficacy and safety of cefprozil and amoxycillin/clavulanate in the treatment of acute otitis media in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Cefpodoxime proxetil compared with amoxicillin-clavulanate for the treatment of otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Double-blind comparison of cefixime and cefaclor in the treatment of acute otitis media in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparative evaluation of loracarbef and amoxicillin-clavulanate for acute otitis media

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Loracarbef: a new orally administered carbacephem antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Streptococcal Pharyngitis: Current Therapy and Criteria for Evaluation of New Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Treatment of pharyngitis and tonsillitis with cefprozil: review of three multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Cefprozil versus penicillin V in treatment of streptococcal tonsillopharyngitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparative efficacy and safety of cefprozil (BMY-28100) and cefaclor in the treatment of acute group A beta-hemolytic streptococcal pharyngitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Five day treatment of pharyngotonsillitis with cefpodoxime proxetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Efficacy and tolerance of cefpodoxime proxetil compared with co-amoxiclav in the treatment of exacerbations of chronic bronchitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Ceftibuten versus cefaclor for the treatment of bronchitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparison of loracarbef (LY163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Orally administered cefpodoxime proxetil for treatment of uncomplicated gonococcal urethritis in males: a dose-response study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Cefixime versus trimethoprim/sulfamethoxazole in treatment of patients with acute, uncomplicated lower urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Loracarbef versus cefaclor in the treatment of urinary tract infections in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparison of cefprozil and cefaclor for treatment of acute urinary tract infections in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Single-dose cefuroxime axetil versus multiple-dose cefaclor in the treatment of acute urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparison of oral cefpodoxime proxetil and cefaclor in the treatment of skin and soft tissue infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Comparative in vitro activities of several new fluoroquinolones and beta-lactam antimicrobial agents against community isolates of Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Management of infections caused by antibiotic-resistant Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Determinants of non-compliance with short term antibiotic regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

A Review of the Pharmacokinetics of Cefpodoxime Proxetil

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Cefixime vs Amoxicillin in the Treatment of Acute Otitis Media in Infants and Children

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Treatment of Sinus Empyema in Adults: A Coordinated Nordic Multicenter Trial of Cefixime vs. Cefaclor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Review of clinical experience in the United States with cefpodoxime proxetil in adults with uncomplicated urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

Cefpodoxime Proxetil in the Treatment of Skin and Soft Tissue Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809603000310

10.1177/106002809603000310

21 January 2018

Identifiers

DOI

1 reference

release_tplh2b54hfdytei4ly2vuda564

27 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tplh2b54hfdytei4ly2vuda564

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference